Pentostatin
Nipent, Pentostatin (pentostatin) is a small molecule pharmaceutical. Pentostatin was first approved as Nipent on 1991-10-11. It is used to treat hairy cell leukemia in the USA. The pharmaceutical is active against adenosine deaminase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Nipent, Pentostatin (discontinued: Pentostatin)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nipent | New Drug Application | 2024-09-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hairy cell leukemia | — | D007943 | C91.4 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9268 | Injection, pentostatin, 10 mg |
Clinical
Clinical Trials
61 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 7 | 20 | 2 | 1 | 1 | 27 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 4 | 18 | 1 | 1 | — | 22 |
| Lymphoid leukemia | D007945 | — | C91 | 3 | 11 | 1 | 1 | 1 | 16 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | 2 | 10 | 4 | — | — | 14 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | 5 | 1 | — | 1 | 7 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 4 | 1 | — | 1 | 6 |
| Hematologic neoplasms | D019337 | — | — | 2 | 5 | 1 | — | — | 6 |
| Immune system diseases | D007154 | — | D89.9 | — | 4 | 1 | — | — | 5 |
| Bronchiolitis obliterans syndrome | D000092122 | — | D89.811 | — | 3 | 2 | — | — | 5 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 4 | 1 | — | — | 5 |
| Hodgkin disease | D006689 | — | C81 | — | 4 | 1 | — | — | 5 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 3 | 1 | — | — | 4 |
| Myeloid leukemia | D007951 | — | C92 | — | 1 | 1 | — | 1 | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 5 | 20 | — | — | — | 21 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | 5 | — | — | — | 6 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 2 | 5 | — | — | — | 5 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 5 | — | — | — | 5 |
| Follicular lymphoma | D008224 | — | C82 | 2 | 4 | — | — | — | 4 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 2 | 3 | — | — | — | 3 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 2 | — | — | — | 3 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | 3 | — | — | — | 3 |
| T-cell lymphoma peripheral | D016411 | — | — | — | 3 | — | — | — | 3 |
| Aplastic anemia | D000741 | — | D61.9 | 2 | 2 | — | — | — | 3 |
Show 54 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemoglobinopathies | D006453 | — | D58.2 | 1 | — | — | — | — | 1 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Acute disease | D000208 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pentostatin |
| INN | pentostatin |
| Description | Pentostatin (or deoxycoformycin, trade name Nipent, manufactured by SuperGen) is an anticancer chemotherapeutic drug.
|
| Classification | Small molecule |
| Drug class | enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 53910-25-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1580 |
| ChEBI ID | — |
| PubChem CID | 439693 |
| DrugBank | DB00552 |
| UNII ID | 395575MZO7 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,533 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nipent
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
986 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use